This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

NCT00059722 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: ZD6474
DRUG: Placebo
DRUG: ZD1839

Sponsor

Genzyme, a Sanofi Company